SCHEDULE: Activist Investors Exit MEI Pharma Board, Reduce Stake Following Private Placement

A group of activist investors, including Funicular Funds and Anson Funds, has terminated their cooperation agreement with MEI Pharma, Inc. and seen their board representative resign after their collective beneficial ownership fell below 5% due to a recent private placement.

Summary

• The Schedule 13D Amendment No. 9 reports the termination of a Cooperation Agreement and a Group Agreement between MEI Pharma, Inc. and a group of activist investors, including Funicular Funds, LP and various Anson entities.
• The termination was effective July 22, 2025, triggered by the Reporting Persons ceasing to own the 'Minimum Ownership Amount' as defined in the Cooperation Agreement.
• This reduction in ownership resulted from a private placement offering by MEI Pharma, Inc., which closed on July 22, 2025, diluting the investors' stake.
• Taheer Datoo, the investors' representative, resigned from MEI Pharma's Board of Directors, effective July 22, 2025, in accordance with the Cooperation Agreement terms.
• As of July 22, 2025, the Reporting Persons ceased to beneficially own more than 5% of MEI Pharma's outstanding shares, which totaled 29,879,755 shares.
• Funicular Funds, LP sold 576,140 shares of Common Stock at a price of $6.3014 per share on July 23, 2025.
• Current beneficial ownership as of July 23, 2025, for the remaining individual reporting persons includes: Funicular Funds, LP, Cable Car Capital, LP, and Jacob Ma-Weaver collectively owning 35,300 shares (0.1%); Anson Investments Master Fund LP and AIMF GP LLC collectively owning 841,674 shares (2.8%); Anson East Master Fund LP and AEMF GP LLC collectively owning 214,304 shares (0.7%); Anson Opportunities Master Fund LP and AOMF GP, LLC collectively owning 37,210 shares (0.1%); and Anson Funds Management LP, Anson Management GP LLC, Tony Moore, Anson Advisors Inc., Amin Nathoo, and Moez Kassam collectively owning 1,093,188 shares (3.7%).

Sentiment

Score: 4

Explanation: The sentiment is slightly negative. The disengagement of an activist investor group, marked by the termination of cooperation agreements, the resignation of their board representative, and a significant share sale by one of the entities, generally signals a reduction in institutional confidence or strategic alignment, which can be viewed unfavorably by the market.

Negatives

• The activist investor group has significantly reduced its influence over MEI Pharma, with their collective beneficial ownership falling below 5%.
• Taheer Datoo, the activist group's representative, has resigned from MEI Pharma's Board of Directors, removing a source of direct oversight and potential strategic input from these investors.
• Funicular Funds, LP, a member of the former activist group, sold a substantial block of 576,140 shares on July 23, 2025, indicating a further reduction in their position and potentially a lack of conviction.

Risks

• Loss of activist investor oversight and strategic guidance could impact future corporate governance and strategic direction.
• The market may react negatively to the reduction in institutional investor interest and the sale of shares by a key reporting entity.
• The private placement offering, while providing capital, may have resulted in dilution for existing shareholders.

Future Outlook

The filing does not provide forward-looking statements or guidance from MEI Pharma, Inc. It primarily details the cessation of a specific activist investor group's beneficial ownership and related agreements.

Industry Context

This filing reflects a common dynamic in the biotechnology and pharmaceutical industry where companies, often in need of capital for R&D and operations, undertake private placements. Such events can dilute existing shareholders and alter the landscape of significant institutional ownership, sometimes leading to the disengagement of activist investors who may have previously sought to influence corporate strategy or governance.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: May experience reduced activist oversight and potential dilution from the private placement. The share sale by Funicular Funds, LP could signal reduced confidence.
• Management: May have increased autonomy without the formal constraints of the Cooperation Agreement, but also loses the strategic input or pressure from the activist group.

Next Steps

• The Reporting Persons are no longer members of the Schedule 13D group and will cease to be Reporting Persons immediately upon the filing of this Amendment No. 9, implying no further Schedule 13D amendments from this group.

Key Dates

Recommendation

The filing indicates a significant reduction in activist investor influence over MEI Pharma, marked by the termination of key agreements and the resignation of their board representative. Furthermore, one of the reporting entities sold a substantial number of shares. While the private placement provides capital, the disengagement of a prominent activist group and a share sale are generally not positive signals for a stock. Investors should hold to assess the company's performance and strategic direction without this activist involvement, and monitor for further market reactions to these developments.

Keywords

MEI Pharma, Schedule 13D, Activist Investor, Beneficial Ownership, Corporate Governance, Private Placement, Share Sale, Board Resignation, Cooperation Agreement, Group Agreement